Lambda Biologics
Lambda Biologics GmbH is a German contract research organization offering patient-derived organoid and tumor-microenvironment co-culture services for drug discovery, immunotherapy evaluation, cosmetics testing, and academic research, serving pharma, biotech, cosmetics, and academic clients globally.
- Company typePrivate
- Founded-
- HeadquartersLeipzig, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Lambda Biologics does
Lambda Biologics GmbH is a privately held German contract research organization headquartered in Leipzig that provides organoid-based in vitro testing services for drug discovery, disease modeling, and non-animal safety assessment. The company's core offering is built on a patient-derived organoid platform that generates three-dimensional cell culture models preserving tumor heterogeneity and patient-specific genetic alterations, combined with immune cell and stromal cell integration (TILs, cytotoxic T cells, regulatory T cells, macrophages, CAFs) to recreate tumor microenvironments for immuno-oncology evaluation. A registered patent on TIL + organoid co-culture methodology for anticancer drug efficacy testing is positioned by the company as globally unique, and the offering extends to a curated organoid biobank, the MyLab cloud platform for project management and data analysis, and supporting technical services in molecular biology, bioinformatics, spatial biology, and live 3D imaging. The customer base spans pharmaceutical and biotechnology companies (drug discovery, immunotherapy evaluation, ADC efficacy testing), cosmetics firms (non-animal testing for K-Beauty), food industry players (functional ingredient and probiotic testing via ODISEI-Gut), and academic and clinical research institutions across Korea, Germany, the US, and Australia.
The company monetizes through a project-based CRO model with per-assay pricing ranging from approximately €6,000 (cytotoxic T cell co-culture) to €9,057+ (TIL service), supplemented by a recurring-access organoid banking system. Go-to-market is sales-led via direct quote requests through the MyLab platform, conference engagement (AACR 2026 Booth 1603, ODC26 Seoul, IFSCC 2026), and content marketing across LinkedIn, YouTube, Instagram, and a company blog. Recent commercial activity includes four product launches in the first half of 2026 across immuno-oncology, ADC evaluation, gut health, and CAF co-culture, indicating active expansion of the service catalog rather than evidence of scaled recurring enterprise revenue.
Lambda Biologics firmographics
Firmographics- Name
- Lambda Biologics
- Legal name
- Lambda Biologics GmbH
- Website
- https://afs.lambda-bio.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lambda Biologics GmbH is a German contract research organization offering patient-derived organoid and tumor-microenvironment co-culture services for drug discovery, immunotherapy evaluation, cosmetics testing, and academic research, serving pharma, biotech, cosmetics, and academic clients globally.
- Ownership category
- akta.pro rank
Lambda Biologics industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- Cell Therapy Developers (Autologous) (HLAAABAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Lambda Biologics is headquartered
LocationHeadquarters
- HQ city
- Leipzig
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Lambda Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Organoid Services and Research: Contract research organization providing organoid-based drug evaluation services to pharmaceutical companies, biotechnology firms, and academic institutions. Services are priced per project or per assay type, with pricing starting from 6,000-9,000+ EUR per service.
- Organoid Banking System: Access to curated library of ready-to-use organoids - standardized, scalable organoids for in vitro research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Regulatory T cell co-culture service |
| Unit Pricing | Pay-as-you-go | Tumor-Infiltrating Lymphocyte (TIL) service |
| Unit Pricing | Pay-as-you-go | Cytotoxic T cell co-culture service |
| Unit Pricing | Pay-as-you-go | Organoid Custom Projects |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Lambda Biologics product offering
Product offeringCore offering
Lambda Biologics is a contract research organization providing organoid-based in vitro drug evaluation services and disease modeling. It supplies patient-derived normal and cancer organoids, custom organoid co-culture assays with immune and stromal cells, and analytical services (molecular biology, bioinformatics, spatial biology, live 3D imaging), delivered through direct project engagements quoted via its MyLab platform.
Product overview
Lambda Biologics is a specialized contract research organization (CRO) offering organoid-based in vitro solutions for drug discovery and disease modeling. The company's portfolio is organized into three main service pillars: (1) Organoid Service covering normal organoids (lung, gastric, liver, midbrain, cerebral, retinal, adenoid), cancer organoids (colorectal, lung, pancreatic, breast, gastric, ovarian, endometrial, hepatocellular carcinoma), and disease modeling; (2) Research Service including cosmetics testing, OECD TG testing, and zebrafish models; and (3) Technical Service encompassing molecular biology, bioinformatics, spatial biology, and live 3D imaging. The platform is supported by MyLab, a cloud-based research platform featuring an organoid banking system, Lambda Cloud for data management, and experimental design consultancy. Advanced immuno-oncology offerings include co-culture services with cytotoxic T cells, tumor-infiltrating lymphocytes (TILs), regulatory T cells, macrophages (M1/M2), and cancer-associated fibroblasts (CAFs) for tumor microenvironment modeling. Additional specialized services include ADC efficacy/toxicity evaluation, MDSC infiltration assays, and the ODISEI-Gut intestinal platform.
Differentiator
Problem solved
Functional benefit
Brands
- MyLab: A cloud-based platform for experimental design consultancy, organoid banking system, and data storage/analysis.
- ODISEI-Gut
- ODISEI Platform
Quantifiable outcome
- Results delivered in less than one month for CRC organoid projects
- +1 more outcomes
Companies that use Lambda Biologics
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles3 records
Lambda Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Lambda Biologics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- MyLab PlatformcoreMyLab is Lambda Biologics' proprietary cloud-based platform providing experimental design consultancy, organoid banking system access, and Lambda Cloud for data storage and analysis. It serves as the primary customer interface for project management and service delivery.
- KAIST (Korea Advanced Institute of Science and Technology)coreCollaborative research partnership for colorectal cancer (CRC) organoid drug development workflows. KAIST researchers utilized Lambda Biologics' CRC organoid platform to validate lomitapide as a potential anticancer therapy, demonstrating organoid-based preclinical validation within integrated drug development workflows.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Lambda Biologics competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Large global CRO offering extensive preclinical services including organoid-based safety and efficacy testing, alongside broader discovery, safety assessment, and manufacturing services. Comparable as an incumbent offering organoid services within a much wider preclinical portfolio, competing for the same enterprise pharma customers.
- Molecular Devices (Danaher): Danaher-owned provider of high-content imaging and 3D organoid analysis instruments used in organoid-based drug screening workflows. Comparable as an incumbent serving the same pharma/biotech customers with organoid imaging and analysis capabilities adjacent to Lambda's Live&3D Imaging services.
- Stemcell Technologies: Major life-science tools company providing organoid culture media, reagents, and supporting services used by organoid researchers globally. Comparable as an incumbent enabling the organoid research ecosystem with overlapping pharma and academic customer base, though operating in tools/reagents rather than CRO services.
Direct peers
- Definigen: Provider of human iPSC-derived cell models and organoid services for drug discovery, with focus on liver, intestinal, and disease-specific models. Comparable as a specialty organoid CRO serving pharma and biotech with similar disease modeling and toxicity testing offerings.
- InSphero: Swiss-based provider of 3D in vitro models including organoids, microtissues, and spheroids for drug safety and efficacy testing. Directly comparable as a specialty 3D in vitro CRO with overlapping pharma/biotech customer base and similar non-animal testing value proposition.
- Crown Bioscience: Global CRO offering patient-derived xenograft (PDX) and organoid-based preclinical oncology services for pharma and biotech. Directly comparable to Lambda Biologics as both provide human-relevant in vitro/ex vivo tumor models for drug discovery, with overlapping customer base in immuno-oncology and ADC evaluation.
- Hubrecht Organoid Technology (HUB): Pioneer in organoid technology with foundational patents around Lgr5+ stem-cell-derived organoids; offers organoid biobanking, disease modeling, and drug screening services. Directly comparable as a specialty organoid CRO with biobank and disease modeling offerings serving pharma and academic customers.
Emerging players
- XCell Science: Provider of iPSC-derived neural and disease organoids for neuroscience drug discovery and toxicology. Comparable as a niche organoid CRO with overlap in disease modeling services (neural organoids), targeting similar pharma/biotech and academic customers in specialty indications.
- Cellesce: UK-based company developing scalable organoid expansion technologies for drug discovery and disease modeling. Comparable as an emerging player in patient-derived organoid services with overlapping focus on biobank scalability and pharma partnerships.
- Cypre Holdings: Developer of patient-derived tumor organoid platforms for high-throughput drug screening and predictive oncology. Comparable as an emerging player in patient-derived organoid services with overlapping pharma/biotech customer base and similar focus on translational drug response prediction.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Lambda Biologics social profiles
Digital presenceLambda Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lambda Biologics leadership team
Management profileNumber of profiles
Lambda Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lambda Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lambda Biologics
What does Lambda Biologics do?
Lambda Biologics is a contract research organization providing organoid-based in vitro drug evaluation services and disease modeling. It supplies patient-derived normal and cancer organoids, custom organoid co-culture assays with immune and stromal cells, and analytical services (molecular biology, bioinformatics, spatial biology, live 3D imaging), delivered through direct project engagements quoted via its MyLab platform.
Is Lambda Biologics a public or private company?
Lambda Biologics is a private company. It is classified as unknown and is currently operating.
When was Lambda Biologics founded?
Lambda Biologics was founded in -1. It employs 1 to 10 people.
Where is Lambda Biologics based?
Lambda Biologics is headquartered in Leipzig, Germany, in the Europe region.
How does Lambda Biologics make money?
Two revenue lines are on record. Organoid Services and Research is the primary driver. The others are organoid Banking System.
Who are Lambda Biologics's main competitors?
Broad incumbents on record are Charles River Laboratories, Molecular Devices (Danaher) and Stemcell Technologies. Direct peers are Definigen, InSphero, Crown Bioscience and Hubrecht Organoid Technology (HUB). Emerging players are XCell Science, Cellesce and Cypre Holdings.
Does Lambda Biologics have an API?
No public API is recorded for Lambda Biologics.
What industry is Lambda Biologics in?
Lambda Biologics's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 8731.